Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRADA-II
2024-515323-11-00Phase 2Authorised
- Sponsor
- Akershus University Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Entresto plus anthracycline-containing cancer therapy with Placebo plus anthracycline-containing cancer therapy (2 arms). Primary endpoint: Change in left ventricular ejection fraction by cardiac MRI. Planned start Nov 2024; status: authorised.
02
Drugs
sacubitril + valsartan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-515323-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515323-11-00.